Multiple.packs for collection of blood. Left to right: transfer pack containing optimal additive solution; primary pack containing 450 ml of blood in anticoagulant; and pack for collection of platelets with extended shelf ife.
Preparation of platelet and granulocyte concentrates
Platelet and granulocyte concentrates can be prepared by collecting blood from a single donor into one of three interconnected packs; alternatively, a blood cell processor may be used to collect platelets or leucocytes directly from a donor. The final product may be left in a single pack, or pooled concentrates may be prepared from several donations. In special circumstances (described below) both platelet and granulocyte concentrates can be collected from donors whose platelet or granulocyte antigens, or both (for example, human leucocyte antigen-HLA) are matched with the patient's antigens.
Properties ofplatelet concentrates Method of collection

Property
From whole blood By cell separator Volume (ml) is equivalent to six units of platelets) may be given. The efficiency of each platelet transfusion should be checked by clinical observation and by calculating the "corrected platelet increment." * Equipment-Platelet concentrate can be transfused through a standard blood administration set; if it is available, however, a platelet administration set is preferable.
Adverse effects ofplatelet transfusion The main adverse effects of platelet transfusion are the development of platelet refractoriness, alloimmunisation, transmission of disease (to be dealt with elsewhere), and-rarely-graft versus host disease. * Platelet refractoriness-Over two thirds of recipients receiving multiple transfusions of platelet concentrate from random donors become alloimmunised to HLA and will become "refractory," in that the expected platelet increment will not be achieved because of rapid immune destruction of the transfused platelets, usually by antibodies to HLA. Refractoriness may be defined as the failure of two consecutive transfusions to give a corrected increment of greater than 7-5 x 109/1 one hour after transfusion in the absence of fever, infection, severe haemorrhage, splenomegaly, or disseminated intravascular coagulation. Before labelling a patient "refractory" the viability, dose, and method of administration of the platelets should be checked. The presence of antibodies to HLA in the patient's serum should be confirmed by lymphocyte toxicity testing, and that of anti-PIP excluded by a platelet immunofluorescent test. All patients with indications for platelet transfusion who meet the above definition of refractoriness should if possible receive HLA compatible platelet concentrate collected from appropriately matched donors with a blood cell separator.
At present, prevention of platelet refractoriness can be achieved by giving red cell and platelet concentrates that contain less than 107 white cells, which is the minimum number of white cells required for immunisation against HLA antigens. There are several types of filter on the market that can be used for depleting the numbers of white cells in concentrates Administration ofgranulocyte concentrate transfusions It is reasonable to attempt a three day trial of granulocyte concentrate transfusions in patients with the above indications. If there is a good response, the transfusions may be continued.
ABO and Rhesus specific granulocyte concentrate should be used, and red cell compatibility testing against the patient's serum carried out because of the high red cell content of the product. Transfusion of 1010 granulocytes/day is an effective dose: this is equivalent to one donation collected by the blood cell separator or to granulocyte concentrate (buffy coat) harvested from 12-18 single units of whole blood. Hydrocortisone 100 mg and chlorpheniramine 10 mg should be given intravenously before infusion to prevent an immediate febrile transfusion reaction.
Adverse effects ofgranulocyte transfusions * Alloimmunisation -Granulocyte concentrate provides a powerful antigenic stimulus, and most patients develop HLA and granulocyte specific antibodies. These cause platelet refractoriness and severe nonhaemolytic febrile transfusion reactions if the patient has further transfusions of blood or blood components. Febrile reactions should be treated by slowing or stopping the infusion and giving hydrocortisone 100 mg and chlorpheniramine 10 mg intravenously. * Transmission ofinfection -It is important to note that the risk of transmission of cytomegalovirus is particularly high with granulocyte concentrate transfusions because the latent virus is present in the white cells of subjects who have had the infection in the past. Patients at risk of becoming infected with cytomegalovirus, therefore, should be given granulocyte concentrate only from cytomegalovirus seronegative donors. * Pulmonary infiltration -This is a serious complication of granulocyte concentration transfusions and may include fluid overload with pulmonary oedema, antibody mediated granulocyte sequestration in the lungs, and exacerbation of pre-existing pulmonary infection. In most cases the patients remain symptom free; in the most severe form, however, the adult respiratory distress syndrome may ensue and some patients may require ventilatory and cardiovascular support. 
